Positive Phase 3 Results for Novel Schizophrenia Drug
The investigational agent xanomeline-trospium (KarXT, Karuna Therapeutics), which combines a muscarinic receptor agonist with an anticholinergic agent, helps improve psychosis symptoms, and is not associated with weight gain or sedation in adults with schizophrenia, new research shows. Top-line results from the phase 3 EMERGENT-2 trial showed a significantly greater reduction from baseline on Positive and … Read more